Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioheart, Inc.
Cardiology company adds employees with expansion of cell transplantation trials
December 7th, 2004
Bioheart, Inc., announced that it has added a number of people to its clinical and research teams coinciding with expansion of its cell transplantation clinical trials and internal research and development programs. Bioheart is focused on regenerating damaged heart muscle with its MyoCell myogenic cell composition (adult muscle stem cells - myoblasts), which is catheter delivered. Clinical studies of Bioheart's MyoCell product began in Europe in May of 2001 and in the U.S.A in 2003. Results from these studies will be presented at next week's American Heart Association Annual Meeting in New Orleans. Positive results from these previous low dose safety...
Source: Cardiovascular Business Week (2004-12-07)
|
